MX370586B - Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. - Google Patents
Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes.Info
- Publication number
- MX370586B MX370586B MX2017010422A MX2017010422A MX370586B MX 370586 B MX370586 B MX 370586B MX 2017010422 A MX2017010422 A MX 2017010422A MX 2017010422 A MX2017010422 A MX 2017010422A MX 370586 B MX370586 B MX 370586B
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- antioxidant
- iflammation
- imidazolyl
- compounds
- Prior art date
Links
- 239000003963 antioxidant agent Substances 0.000 title abstract 2
- 230000003078 antioxidant effect Effects 0.000 title abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Abstract
En la presente se describen compuestos de la fórmula: (ver Fórmula) donde las variables se definen en la presente; también se proporcionan sus composiciones farmacéuticas; en algunos aspectos, los compuestos y las composiciones provistas en la presente se pueden usar como moduladores de la inflamación antioxidantes; en algunos aspectos, la presente descripción proporciona métodos donde los compuestos y la composición descritos en la presente se usan para el tratamiento de enfermedades y trastornos asociados con inflamación y cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562115247P | 2015-02-12 | 2015-02-12 | |
PCT/US2016/017769 WO2016130927A1 (en) | 2015-02-12 | 2016-02-12 | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017010422A MX2017010422A (es) | 2018-06-06 |
MX370586B true MX370586B (es) | 2019-12-17 |
Family
ID=55442884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010422A MX370586B (es) | 2015-02-12 | 2016-02-12 | Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. |
Country Status (12)
Country | Link |
---|---|
US (1) | US11059792B2 (es) |
EP (1) | EP3256451B1 (es) |
JP (1) | JP6748652B2 (es) |
KR (2) | KR20240035818A (es) |
CN (1) | CN107428698B (es) |
AU (1) | AU2016219109B2 (es) |
CA (1) | CA2974726C (es) |
EA (1) | EA038328B1 (es) |
IL (1) | IL253923B (es) |
MX (1) | MX370586B (es) |
NZ (1) | NZ734292A (es) |
WO (1) | WO2016130927A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2276493T3 (pl) | 2008-04-18 | 2019-05-31 | Reata Pharmaceuticals Inc | Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17 |
ES2861393T3 (es) | 2012-04-27 | 2021-10-06 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
CN112654610A (zh) * | 2018-06-15 | 2021-04-13 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
US20210147380A1 (en) * | 2018-06-20 | 2021-05-20 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
AU2003235676A1 (en) | 2002-01-15 | 2003-07-30 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
AU2003303128A1 (en) | 2002-05-13 | 2004-08-13 | Trustees Of Dartmouth College | Inhibitors and methods of use thereof |
WO2006089406A1 (en) | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
EP2094651A1 (en) | 2006-11-17 | 2009-09-02 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
WO2008064132A2 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
WO2009089545A1 (en) | 2008-01-11 | 2009-07-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
EA022588B1 (ru) | 2008-04-18 | 2016-01-29 | Ритэ Фамэсутикл, Инк. | Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце |
PL2276493T3 (pl) | 2008-04-18 | 2019-05-31 | Reata Pharmaceuticals Inc | Antyoksydacyjne modulatory stanu zapalnego: pochodne kwasu oleanolowego z amino- i innymi modyfikacjami przy C-17 |
BRPI0911422B8 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos |
BRPI0911105B1 (pt) | 2008-04-18 | 2022-11-08 | Reata Pharmaceuticals, Inc | Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos |
CA2731650A1 (en) | 2008-07-22 | 2010-01-28 | Tadashi Honda | Monocyclic cyanoenones and methods of use thereof |
US8778990B2 (en) | 2008-11-04 | 2014-07-15 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
TR201909743T4 (tr) | 2009-02-13 | 2019-07-22 | Reata Pharmaceuticals Inc | Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri. |
CA2795320C (en) | 2010-04-12 | 2019-01-22 | Reata Pharmaceuticals, Inc. | Method of treating obesity using antioxidant inflammation modulators |
TWI527788B (zh) | 2010-12-17 | 2016-04-01 | 瑞塔醫藥有限責任公司 | 作為抗氧化發炎調節劑之吡唑及嘧啶三環烯酮 |
UY33946A (es) | 2011-03-11 | 2012-08-31 | Reata Pharmaceuticals Inc | Derivados de c4-monometil triterpenoides y sus métodos de uso |
ES2861393T3 (es) | 2012-04-27 | 2021-10-06 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones |
WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
PL2892912T3 (pl) | 2012-09-10 | 2019-10-31 | Reata Pharmaceuticals Inc | C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
CN104768965B (zh) | 2012-09-10 | 2018-05-11 | 里亚塔医药公司 | 齐墩果酸的c17-杂芳基衍生物和其使用方法 |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
JP6564372B2 (ja) | 2013-08-23 | 2019-08-21 | リアタ ファーマシューティカルズ インコーポレイテッド | バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 |
WO2015112792A1 (en) * | 2014-01-24 | 2015-07-30 | Abbvie Inc. | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
-
2016
- 2016-02-12 EA EA201791814A patent/EA038328B1/ru unknown
- 2016-02-12 CN CN201680011160.3A patent/CN107428698B/zh active Active
- 2016-02-12 MX MX2017010422A patent/MX370586B/es active IP Right Grant
- 2016-02-12 US US15/548,909 patent/US11059792B2/en active Active
- 2016-02-12 CA CA2974726A patent/CA2974726C/en active Active
- 2016-02-12 KR KR1020247004058A patent/KR20240035818A/ko not_active Application Discontinuation
- 2016-02-12 AU AU2016219109A patent/AU2016219109B2/en active Active
- 2016-02-12 NZ NZ734292A patent/NZ734292A/en unknown
- 2016-02-12 WO PCT/US2016/017769 patent/WO2016130927A1/en active Application Filing
- 2016-02-12 JP JP2017542001A patent/JP6748652B2/ja active Active
- 2016-02-12 EP EP16706722.2A patent/EP3256451B1/en active Active
- 2016-02-12 KR KR1020177023589A patent/KR20170117092A/ko active IP Right Grant
-
2017
- 2017-08-09 IL IL253923A patent/IL253923B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP3256451B1 (en) | 2021-10-20 |
US11059792B2 (en) | 2021-07-13 |
CN107428698A (zh) | 2017-12-01 |
EP3256451A1 (en) | 2017-12-20 |
MX2017010422A (es) | 2018-06-06 |
AU2016219109B2 (en) | 2020-05-14 |
CN107428698B (zh) | 2021-10-26 |
NZ734292A (en) | 2022-09-30 |
JP2018505196A (ja) | 2018-02-22 |
IL253923B (en) | 2021-06-30 |
AU2016219109A1 (en) | 2017-08-24 |
JP6748652B2 (ja) | 2020-09-02 |
EA038328B1 (ru) | 2021-08-10 |
CA2974726C (en) | 2023-09-19 |
KR20240035818A (ko) | 2024-03-18 |
CA2974726A1 (en) | 2016-08-18 |
IL253923A0 (en) | 2017-10-31 |
WO2016130927A1 (en) | 2016-08-18 |
KR20170117092A (ko) | 2017-10-20 |
BR112017017133A2 (pt) | 2018-04-03 |
US20180127380A1 (en) | 2018-05-10 |
EA201791814A1 (ru) | 2017-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
PH12019501443A1 (en) | Benzooxazole derivatives as immunomodulators | |
PH12018502710A1 (en) | Heterocyclic compounds as immunomodulators | |
PH12016501898B1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
MX2021009673A (es) | Moduladores de ror-gamma. | |
WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
MX370586B (es) | Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
PH12015502161A1 (en) | Therapeutic compounds and compositions | |
WO2015184257A3 (en) | Small molecule transcription modulators of bromodomains | |
MX2016001136A (es) | Derivados de oxoquinazolinil-butanamida. | |
MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
MX2016009589A (es) | Enonas piridazolilo y pirimidinilo triciclicas sustituidas con arilo y arilalquilo como moduladores de la inflamacion antioxidantes. | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
MX2020000135A (es) | Nuevos compuestos de quinolinona. | |
MX364859B (es) | Derivados de imidazopirazinona. | |
GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
MX2018005515A (es) | Derivados de 1,4-dicarbonil-piperidilo. | |
MX2017009608A (es) | Compuestos anticancerigenos. | |
WO2017095950A3 (en) | Compounds for treating proliferative diseases | |
MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
MX2022007595A (es) | Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos. | |
MX2015016760A (es) | Derivados de ftalazina. | |
MX2022000781A (es) | Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos. | |
PH12016500824A1 (en) | Compositions and methods for the treatment of viral diseases with pde4 modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |